<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00641186</url>
  </required_header>
  <id_info>
    <org_study_id>H-16378</org_study_id>
    <nct_id>NCT00641186</nct_id>
  </id_info>
  <brief_title>Trial of Xyrem for Excessive Daytime Sleepiness and Sleep Disturbance in Parkinson's Disease (PD)</brief_title>
  <acronym>Xyrem</acronym>
  <official_title>A Phase II, Eight Week, Multi-Center, Open Label Trial of Xyrem(R) (Sodium Oxybate) for Excessive Daytime Sleepiness and Nocturnal Sleep Disturbance in Patients With Mild to Moderate Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jazz Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Baylor College of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial is designed to evaluate the safety and potential efficacy of Xyrem for
      the treatment of excessive daytime sleepiness (EDS) and nocturnal sleep disturbance in
      patients with mild to moderate Parkinson's Disease (PD).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety and tolerability of Xyrem (sodium oxybate) oral solution at nightly doses of 4.5 to 9.0 grams in patients with Parkinson's Disease</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the possible efficacy of Xyrem in the treatment of the sleep disturbances and EDS common in Parkinsonian patients.</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine if Xyrem treatment improves daytime motor symptoms and the overall quality of life in patients with mild to moderate PD.</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>sodium oxybate 4.5 to 9.0 gms per night</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sodium oxybate</intervention_name>
    <description>4.5 to 9.0 grams per night</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Xyrem</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female with a diagnosis of idiopathic PD.

          -  Age between 30 and 75, inclusive. -Hoehn &amp; Yahr Stage 1.5 - 4.0 in the practically
             defined &quot;OFF&quot;. -

          -  History &gt; 2 months of excessive daytime sleepiness confirmed at baseline/screening by
             an Epworth Sleepiness Scale score of &gt; 10.

          -  History &gt; 2 months of nocturnal sleep disturbances consisting of insomnia, fragmented
             sleep and/or non-restorative sleep.

          -  Folstein Mini-Mental State Exam score of &gt; 24.

          -  Birth control for sexually active women of childbearing potential (e.g. abstinence,
             hormonal contraception, barrier method, intrauterine device).

          -  Evidence of a personally signed and dated informed consent form document indicating
             that the subject (or a legally acceptable representative) has been informed of all
             pertinent aspects of the trial.

          -  Subjects who are willing and able to comply with scheduled visits, treatment plan, and
             other study procedures.

          -  Stable dose of medications, defined as no change in dose or regimen of medications for
             at least 3 months prior to Screen Visit.

        Exclusion Criteria:

          -  Known idiopathic sleep pathology: sleep apnea and narcolepsy.

          -  Serious co-morbid disease --Atypical parkinsonism (e.g., Parkinson &quot;plus&quot; syndrome,
             secondary Parkinson's syndrome). --Significant neurological symptoms not accounted for
             by PD. --Significant psychiatric symptoms or dementia.

          -  Sexually active women of childbearing potential without adequate form of birth
             control.

          -  Pregnancy or lactation.

          -  Mini-mental status examination of &lt; 25.

          -  Participation in another clinical trial of another investigational agent or device
             within the previous 60 days.

          -  Current abuse of alcohol or drugs.

          -  Active or prior malignancy other than cutaneous basal cell carcinoma or in situ
             carcinoma of the uterine cervix.

          -  Known hypersensitivity to sodium oxybate or other constituents of the product.

          -  Any medical conditions that are contraindications to the use of sodium oxybate or
             significant hepatic impairment.

          -  Patients being treated with sedative hypnotic agents or other central nervous system
             (CNS) depressants.

          -  Subjects taking warfarin.

          -  Patients with succinic semialdehyde dehydrogenase deficiency.

          -  Subjects who, in the opinion of the investigator, are not able to comply with the
             requirements of the study.

          -  Any other condition that, in the investigator's opinion, would cause a significant
             hazard to the subject.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William G Ondo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 18, 2008</study_first_submitted>
  <study_first_submitted_qc>March 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2008</study_first_posted>
  <last_update_submitted>April 30, 2009</last_update_submitted>
  <last_update_submitted_qc>April 30, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 1, 2009</last_update_posted>
  <responsible_party>
    <name_title>William G. Ondo, MD</name_title>
    <organization>Baylor College of Medicine</organization>
  </responsible_party>
  <keyword>excessive daytime somnolence</keyword>
  <keyword>Parkinson disease</keyword>
  <keyword>sleep disturbance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Dyssomnias</mesh_term>
    <mesh_term>Sleep Wake Disorders</mesh_term>
    <mesh_term>Parasomnias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sodium Oxybate</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>August 23, 2017</submitted>
    <returned>September 19, 2017</returned>
    <submitted>September 19, 2017</submitted>
    <returned>October 19, 2017</returned>
    <submitted>October 31, 2017</submitted>
    <returned>December 4, 2017</returned>
    <submitted>April 5, 2018</submitted>
    <returned>May 7, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

